Personal information

Websites & social links

Stopka lab
BIOCEV
First Faculty of Medicine at BIOCEV

Other IDs

Scopus Author ID: 55914686600
ResearcherID: I-9204-2017

Keywords

molecular biology and genetics, hematology, hematological malignancies, chromatin remodeling, epigenetics, developmental biology

Countries

Czech Republic

Biography

Research focus on transcription and chromatin remodeling factors in hematopoiesis and leukemogenesis (tissue culture and mouse models).

Activities

Collapse all

Employment (3)

Charles University, First Faculty of Medicine: Prague, CZ

2014-01 to present | PhD student, research associate (BIOCEV, First Faculty of Medicine, Charles University in Prague)
Employment
Source: Self-asserted source
Helena Paszeková

Charles University, First Faculty of Medicine : Prague, CZ

2013-09 to 2013-12 | PhD student (Institute of Pathological Physiology, Fisrt Faculty of Medicine, Charles University )
Employment
Source: Self-asserted source
Helena Paszeková

Masaryk University: Brno, CZ

2008-03 to 2013-05 | Intern Student (Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University)
Employment
Source: Self-asserted source
Helena Paszeková

Education and qualifications (2)

Charles University, First Faculty of Medicine: Prague, CZ

2013-09 to present | PhD (BIOCEV)
Education
Source: Self-asserted source
Helena Paszeková

Masaryk University, Faculty of Science: Brno, CZ

2007 to 2013 | MSc
Education
Source: Self-asserted source
Helena Paszeková

Funding (1)

Controlled deletion of candidate oncogene SMARCA5 in a tumor cell

2016 to present | Grant
Charles University Grant Agency (Prague, CZ)
GRANT_NUMBER:

228316
Source: Self-asserted source
Helena Paszeková

Works (4)

Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents

International Journal of Molecular Sciences
2022-06 | Journal article | Author
DOI: 10.3390/ijms23126729
Contributors: Petra Bašová; Helena Paszeková; Ľubomír Minařík; Martina Dluhošová; Pavel Burda; Tomas Stopka
Source: check_circle
Multidisciplinary Digital Publishing Institute

Loss of ISWI ATPase SMARCA5 (SNF2H) in Acute Myeloid Leukemia Cells Inhibits Proliferation and Chromatid Cohesion

International Journal of Molecular Sciences
2020-03 | Journal article | Author
DOI: 10.3390/ijms21062073
Contributors: Tomáš Zikmund; Helena Paszeková; Juraj Kokavec; Paul Kerbs; Shefali Thakur; Tereza Turkova; Petra Tauchmanova; Philipp A. Greif; Tomas Stopka
Source: check_circle
Multidisciplinary Digital Publishing Institute

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

Biomedical Papers
2015 | Journal article
DOI: 10.5507/bp.2015.014
EID:

2-s2.0-84934277443
Contributors: Sevcikova, S.; Paszekova, H.; Besse, L.; Sedlarikova, L.; Kubaczkova, V.; Almasi, M.; Pour, L.; Hajek, R.
Source: Self-asserted source
Helena Paszeková via Scopus - Elsevier

High-risk multiple myeloma: Different definitions, different outcomes?

Clinical Lymphoma, Myeloma and Leukemia
2014 | Journal article
DOI: 10.1016/j.clml.2013.09.004
EID:

2-s2.0-84892793038
Contributors: Paszekova, H.; Kryukov, F.; Kubiczkova, L.; Hajek, R.; Sevcikova, S.
Source: Self-asserted source
Helena Paszeková via Scopus - Elsevier
How many people are using ORCID?